

# Willem J Lesterhuis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3697124/publications.pdf>

Version: 2024-02-01

70  
papers

7,285  
citations

87888

38  
h-index

95266

68  
g-index

71  
all docs

71  
docs citations

71  
times ranked

10054  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dendritic cell immunotherapy: mapping the way. <i>Nature Medicine</i> , 2004, 10, 475-480.	30.7	896
2	Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. <i>Nature Biotechnology</i> , 2005, 23, 1407-1413.	17.5	791
3	Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. <i>Cancer Research</i> , 2003, 63, 12-7.	0.9	659
4	Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics. <i>Clinical Cancer Research</i> , 2014, 20, 2831-2837.	7.0	349
5	Cancer immunotherapy “revisited”. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 591-600.	46.4	346
6	Programmed Death Ligand 2 in Cancer-Induced Immune Suppression. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	282
7	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 3100-3108.	8.2	271
8	Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. <i>Clinical Cancer Research</i> , 2003, 9, 5091-100.	7.0	235
9	Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 5067-5078.	7.0	212
10	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 264-272.	46.4	204
11	Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 5779-5787.	1.6	174
12	Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. <i>Clinical Cancer Research</i> , 2009, 15, 2531-2540.	7.0	172
13	Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients. <i>Clinical Cancer Research</i> , 2011, 17, 5725-5735.	7.0	158
14	Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	147
15	Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells. <i>Journal of Immunotherapy</i> , 2002, 25, 429-438.	2.4	140
16	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination. <i>Cancer Research</i> , 2013, 73, 19-29.	0.9	131
17	Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity. <i>PLoS ONE</i> , 2013, 8, e61895.	2.5	129
18	A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. <i>BMC Cancer</i> , 2017, 17, 684.	2.6	125

#	ARTICLE	IF	CITATIONS
19	Dendritic cell vaccines in melanoma: From promise to proof?. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 118-134.	4.4	113
20	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology</i> , The, 2020, 21, 1213-1223.	10.7	109
21	Chemotherapy and immunotherapy: mapping the road ahead. <i>Current Opinion in Immunology</i> , 2016, 39, 23-29.	5.5	105
22	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 5460-5470.	7.0	86
23	Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. <i>Annals of Oncology</i> , 2006, 17, 974-980.	1.2	85
24	Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. <i>International Journal of Cancer</i> , 2006, 120, 978-984.	5.1	82
25	Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 249-260.	4.2	68
26	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. <i>OncImmunology</i> , 2016, 5, e1057673.	4.6	67
27	Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. <i>Anticancer Research</i> , 2010, 30, 5091-7.	1.1	67
28	Early identification of antigen-specific immune responses in vivo by [ <sup>18</sup> F]-labeled 3- <sup>18</sup> F-fluoro-3- <sup>18</sup> F-deoxy-thymidine ([ <sup>18</sup> F]FLT) PET imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18396-18399.	7.1	65
29	Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. <i>European Journal of Immunology</i> , 2015, 45, 49-59.	2.9	64
30	Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. <i>Scientific Reports</i> , 2015, 5, 12298.	3.3	63
31	A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. <i>British Journal of Cancer</i> , 2010, 103, 1415-1421.	6.4	60
32	Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. <i>Clinical Cancer Research</i> , 2013, 19, 1525-1533.	7.0	58
33	Vascular Endothelial Growth Factor in Systemic Capillary Leak Syndrome. <i>American Journal of Medicine</i> , 2009, 122, e5-e7.	1.5	57
34	Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. <i>Frontiers in Immunology</i> , 2020, 11, 587014.	4.8	56
35	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 223.	4.8	54
36	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma. <i>Cancer Research</i> , 2012, 72, 6102-6110.	0.9	50

#	ARTICLE	IF	CITATIONS
37	PD-L2 is predominantly expressed by Th2 cells. <i>Molecular Immunology</i> , 2011, 49, 1-3.	2.2	46
38	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	4.2	42
39	The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1101-1111.	4.2	41
40	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 584423.	4.8	39
41	Combination immune checkpoint blockade as an effective therapy for mesothelioma. <i>Oncolmmunology</i> , 2018, 7, e1494111.	4.6	37
42	Transient Treg depletion enhances therapeutic anti-cancer vaccination. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 16-28.	2.7	33
43	STATing the importance of immune modulation by platinum chemotherapeutics. <i>Oncolmmunology</i> , 2012, 1, 234-236.	4.6	31
44	Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. <i>Oncolmmunology</i> , 2015, 4, e1011492.	4.6	26
45	Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1109-1115.	4.2	25
46	In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1667-1676.	4.2	24
47	Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. <i>Oncolmmunology</i> , 2019, 8, e1641390.	4.6	22
48	The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. <i>BMC Cancer</i> , 2014, 14, 969.	2.6	20
49	Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. <i>Nature Protocols</i> , 2020, 15, 1628-1648.	12.0	19
50	Restoration of defective cross-presentation in tumors by gemcitabine. <i>Oncolmmunology</i> , 2015, 4, e1005501.	4.6	16
51	Acute generalised exanthematous pustulosis mimicking septic shock. <i>American Journal of Medicine</i> , 2004, 116, 574-575.	1.5	15
52	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , 2017, 8, 54434-54443.	1.8	13
53	Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. <i>Journal of Translational Medicine</i> , 2014, 12, 245.	4.4	12
54	Mouse models of mesothelioma: strengths, limitations and clinical translation. <i>Lung Cancer Management</i> , 2014, 3, 397-410.	1.5	9

#	ARTICLE	IF	CITATIONS
55	Malignant Pleural Effusionsâ€”A Window Into Local Anti-Tumor T Cell Immunity?. <i>Frontiers in Oncology</i> , 2021, 11, 672747.	2.8	9
56	Protocol of DREAM3R: DuRvalumab with chemotherapy as first-line treatment in advanced pleural Mesotheliomaâ€”a phase 3 randomised trial. <i>BMJ Open</i> , 2022, 12, e057663.	1.9	9
57	Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment. <i>Anti-Cancer Drugs</i> , 2012, 23, 139-140.	1.4	8
58	Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?. <i>Lung Cancer Management</i> , 2014, 3, 443-457.	1.5	8
59	Comment on â€œDrug Discovery: Turning the Titanicâ€. <i>Science Translational Medicine</i> , 2014, 6, 229le2.	12.4	7
60	Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. <i>BMC Research Notes</i> , 2018, 11, 864.	1.4	7
61	Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 849793.	2.8	7
62	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
63	Colitis in an alcohol-dependent woman. <i>Lancet, The</i> , 2007, 369, 2050.	13.7	5
64	Chemoimmunotherapy: still waiting for the magic to happen. <i>Lancet Oncology, The</i> , 2014, 15, 780-781.	10.7	5
65	EBV-related lymphoproliferative disorders in immunocompetent patients. <i>Leukemia</i> , 2003, 17, 2537-2538.	7.2	4
66	Functional genomics in cancer immunotherapy: computational approaches for biomarker and drug discovery. <i>Molecular Systems Design and Engineering</i> , 2019, 4, 689-700.	3.4	3
67	Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	3
68	Immune Stimulatory Features of Classical Chemotherapy. , 2013, , 395-414.		2
69	Acute arterial occlusion after chemotherapy for testicular cancer. <i>Lancet Oncology, The</i> , 2005, 6, 910.	10.7	1
70	New directions in mesothelioma treatment. <i>Lung Cancer Management</i> , 2015, 4, 299-307.	1.5	1